Treatment of Acute Myelogenous Leukemia

Alexander A. Morley; Habib Ghaddar; Paolo Anderlini; Elihu Estey; Barry Meisenberg; Robert Zittoun; Franco Mandelli; Stefan Suciu

doi:10.1056/NEJM199506223322515

Treatment of Acute Myelogenous Leukemia

Alexander A. Morley, Habib Ghaddar, Paolo Anderlini, Elihu Estey, Barry Meisenberg, Robert Zittoun, Franco Mandelli, Stefan Suciu

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: The report by Zittoun et al. (Jan. 26 issue)¹ on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.

Original language	English (US)
Pages (from-to)	1717-1719
Number of pages	3
Journal	New England Journal of Medicine
Volume	332
Issue number	25
DOIs	https://doi.org/10.1056/NEJM199506223322515
State	Published - Jun 22 1995
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM199506223322515

Cite this

@article{758b215a30c14142a4af1dd245a9f05c,

title = "Treatment of Acute Myelogenous Leukemia",

abstract = "To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.",

author = "Morley, {Alexander A.} and Habib Ghaddar and Paolo Anderlini and Elihu Estey and Barry Meisenberg and Robert Zittoun and Franco Mandelli and Stefan Suciu",

year = "1995",

month = jun,

day = "22",

doi = "10.1056/NEJM199506223322515",

language = "English (US)",

volume = "332",

pages = "1717--1719",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "25",

}

TY - JOUR

T1 - Treatment of Acute Myelogenous Leukemia

AU - Morley, Alexander A.

AU - Ghaddar, Habib

AU - Anderlini, Paolo

AU - Estey, Elihu

AU - Meisenberg, Barry

AU - Zittoun, Robert

AU - Mandelli, Franco

AU - Suciu, Stefan

PY - 1995/6/22

Y1 - 1995/6/22

N2 - To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.

AB - To the Editor: The report by Zittoun et al. (Jan. 26 issue)1 on a comparison of allogeneic or autologous transplantation and chemotherapy for acute myelogenous leukemia (AML) illustrates a flaw in the study design that is common in trials of treatment for acute leukemia and that limits the clinical usefulness of the conclusions that are drawn. In the trial, all patients with histocompatible donors were assigned to the allogeneic-transplantation group and none were randomly assigned to the other two groups. This design is appropriate for studying the end point of duration of the first remission or of disease-free survival, but.

UR - http://www.scopus.com/inward/record.url?scp=0029026806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029026806&partnerID=8YFLogxK

U2 - 10.1056/NEJM199506223322515

DO - 10.1056/NEJM199506223322515

M3 - Letter

C2 - 7760879

AN - SCOPUS:0029026806

SN - 0028-4793

VL - 332

SP - 1717

EP - 1719

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 25

ER -

Treatment of Acute Myelogenous Leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this